BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
70.24
+0.55 (0.79%)
At close: Jun 26, 2026, 4:00 PM EDT
70.91
+0.67 (0.95%)
After-hours: Jun 26, 2026, 7:59 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 106.42, with a low estimate of 82 and a high estimate of 157. The average target predicts an increase of 51.51% from the current stock price of 70.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 24 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 16 | 16 | 15 | 16 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 22 | 23 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $125 → $98 | Buy | Maintains | $125 → $98 | +39.52% | Jun 17, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $106 → $96 | Buy | Maintains | $106 → $96 | +36.67% | Jun 15, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $101 | Buy | Maintains | $101 | +43.79% | Jun 11, 2026 |
| Barclays | Barclays | Buy Maintains $157 | Buy | Maintains | $157 | +123.52% | Jun 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $104 | Buy | Initiates | $104 | +48.06% | Jun 3, 2026 |
Financial Forecast
Revenue This Year
968.77M
from 502.08M
Increased by 92.95%
Revenue Next Year
1.60B
from 968.77M
Increased by 65.27%
EPS This Year
-2.18
from -3.78
EPS Next Year
0.53
from -2.18
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.1B | 1.9B | |
| Avg | 968.8M | 1.6B | |
| Low | 844.4M | 1.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 120.2% | 95.8% | |
| Avg | 93.0% | 65.3% | |
| Low | 68.2% | 43.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.49 | 2.12 | |
| Avg | -2.18 | 0.53 | |
| Low | -2.62 | -1.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.